Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,774.50
Ask: 1,775.50
Change: 0.00 (0.00%)
Spread: 1.00 (0.056%)
Open: 1,775.50
High: 1,778.50
Low: 1,769.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Flu season prep, complicated by COVID-19, starts early this year

Thu, 13th Aug 2020 13:35

(Adds AstraZeneca details on FluMist vaccine)

By Carl O'Donnell

Aug 13 (Reuters) - Healthcare providers, including CVS
Health Corp, are kicking off flu vaccinations early,
ordering extra shots and aiming to add tests that check for both
the annual flu and COVID-19, pharmacy executives and experts
told Reuters.

Flu vaccination for the fall has taken on increased urgency
because of the potential for serious complications if patients
contract both viruses at once.

Vaccine makers will provide nearly 200 million flu vaccines
to the United States this year, potentially 20% more than is
typical, said LJ Tan, chief strategy officer for the
Immunization Action Coalition, a nonprofit that promotes
vaccination.

CVS expects to more than double the number of flu shots it
provides to around 18 million people and Walgreens Boots
Alliance Inc is stockpiling extra vaccines, the
companies told Reuters.

Drugmaker AstraZeneca Plc on Thursday announced its
first shipment of its FluMist vaccine in the U.S. and said it
has increased production of doses in the U.S. by over 25% more
than previously planned.

Failure to inoculate for the flu could also strain the
United States COVID-19 testing capacity, which is still below
the 6-10 million daily tests needed, Reuters has reported.

"If we can eliminate the dynamic of people getting symptoms
and their first reaction is ‘is this the seasonal flu or is this
COVID,’ it can take demand off of COVID-19 testing," CVS Chief
Executive Larry Merlo told Reuters.

Merlo added that CVS is working to obtain tests that screen
for both viruses simultaneously. U.S. regulators approved a
joint COVID-19 and flu test in July.

The same people who are most vulnerable to risks from
COVID-19, such as the elderly and those with respiratory
conditions, are also at greatest risk for the flu, Tan added.

The U.S. healthcare system is already expected to be
strained in the fall by a resurgence in COVID-19. The Institute
for Health Metrics and Evaluation is anticipating an uptick in
COVID-19 cases in the coming months, resulting in around 300,000
total deaths by December, up from the current figure of roughly
160,000, and a nearly 75% increase in hospitalizations.

There is evidence that social distancing measures for
COVID-19 reduce the transmission rate of the flu as well,
according to the U.S. Centers for Disease Control and
Prevention, meaning that continued measures in the U.S. could
potentially slow flu transmission this season.

However, efforts to inoculate patients for the flu could be
complicated by the need to safeguard patients and healthcare
workers from COVID-19.

"If a patient has a fever or other symptoms associated with
illness, they will be referred to their healthcare provider and
immunizations will be deferred," a Walgreens spokeswoman told
Reuters.

CVS plans to begin inoculating patients earlier than usual -
possibly by the end of this month - to get a jump start on
preparing for this year's flu season, which usually starts
around October.

However, studies show there is a risk that getting
inoculated against the flu too early can leave a patient
vulnerable to contracting the virus later on in winter, if the
shot wears off.

Other physicians are also starting this month, though it
will still take months to fully distribute all the needed
inoculations, Tan said.

The flu vaccine "comes out over time so you want to make
sure people continue to seek flu vaccines" through Thanksgiving
and beyond, Tan said.
(Reporting by Carl O'Donnell; Editing by Peter Henderson,
Aurora Ellis and Bernadette Baum)

More News
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.